INTRODUCTION
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Myelodysplastic syndromes (MDS) are clonal disorders characterized by bone marrow (BM) failure and an increased risk of transformation into acute myeloid leukemia (AML).
Typically, MDS patients are elderly and are already anemic, leucopenic and/or thrombocytopenic upon presentation.
Despite their myeloid origin, many MDS cases show abnormalities in B-cells, usually related to a decrease in the B-cell production and/or an increase in apoptosis (1,2). Such alterations may be due to an increased production demand for essential hematopoietic cells, such as red cells and neutrophils. Alternatively, a blockade on B-cell maturation might occur (2).
A low level of monoclonal B-cells (,5610 9 /L) in otherwise healthy individuals characterizes a condition called monoclonal B-cell lymphocytosis (MBL). The overall reported frequency of MBL is between 0.5% and 12% of adults, depending on the age of the population and the sensitivity of the flow cytometry approach used to detect the B-cell clones (3,4). MBL is more frequently observed among the relatives of patients with familial chronic lymphocytic leukemia (CLL) and in individuals exposed to toxic environments. Although coexistence of CLL and AML or CML has been sporadically reported, the actual frequency of MBL in association with other hematological neoplasias remains to be established.
CASE DESCRIPTION
Here, we report a 61-year-old female patient diagnosed with both MDS and MBL. She complained of a three-month history of fatigue associated with sustained anemia and thrombocytopenia detected on a routine blood test. Splenomegaly or lymphadenomegaly were not observed. Her hemoglobin level was 3.8 g/dL, her absolute white blood cell (WBC) count was 7. 
DISCUSSION
Association of MDS and B-chronic lymphoproliferative disorders (B-CLPD)
is an uncommon finding that has been sporadically described (Table 2) . We found that 31 cases had been reported since 1974. The median age at presentation was 72 years (range: 49-95) and the male-to-female ratio was 1.2:1. Most cases corresponded to patients with MDS and CLL (19/31) and no significant association with specific subtypes of MDS was observed. Florensa et al. showed a frequency of 1% of B-CLPD in a series of 1198 MDS patients (CLL 0.5%, lymphoplasmacytic lymphoma 0.4% and multiple myeloma 0.1%) (7). At present, the general consensus is that these associations may occur randomly (8-10). In line with this idea, we found only one case report supporting the existence of an ontogenic association between both disorders: trisomy 8 was detected in 55% of CD13 + neutrophils and in 13% of CD19 + /CD5 + B lymphocytes in a case with MDS and systemic vasculitis, suggesting a common stem cell precursor had generated the two neoplastic cell populations (11).
Low numbers of circulating monoclonal B-cells in otherwise healthy individuals has been investigated in the last ten years. A MBL diagnosis is confirmed by the presence of ,5610 9 /L monoclonal B-cells associated with a normal physical examination and negative history for lymphoproliferative disease, as observed in our case (12). The progression rate to CLL has been described as approximately 1-2% of MBL cases per year (12). MBL has been observed in a significant number of healthy individuals and in, particular, in elderly people. Despite its frequency, the association of MBL in patients with other hematological neoplastic diseases (e.g., MDS) remains to be established. For the reasons stated above, the coexistence of a monoclonal B-cell disorder with MDS deserves special interest. This is particularly true because multiparameter flow cytometry immunophenotyping is the method of choice to detect MBL. Although numerous reports had described the immunophenotypic abnormalities in MDS, it has only recently begun to be applied during the routine work-up for the diagnosis and prognosis of potential MDS cases (18) . Moreover, our case illustrates the importance of well-designed flow cytometry panels, capable of analyzing all hematopoietic cell populations because more than one neoplastic disorder may be present in the same case. We suggest the addition of one screening tube in the MDS investigational panel, containing CD19, CD5, anti-k and l 
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